Dolastatin-10 in metastatic melanoma

A phase II and pharmokinetic trial of the California Cancer Consortium

Kim Margolin, Jeffrey Longmate, Timothy W. Synold, David R Gandara, Jeffrey Weber, Rene Gonzalez, Mary J. Johansen, Robert Newman, Tracey Baratta, James H. Doroshow

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Dolastatin-10 is a novel pentapeptide agent originally isolated from the marine mollusk Dolabella auricularia with a mechanism of antitumor activity that involves the inhibition of microtubule assembly. We performed a Phase II trial of Dolastatin-10, 400 μg/m2, in patients with advanced melanoma who had received no prior chemotherapy. Dolastatin-10 pharmokinetics were evaluated in a subset of patients following courses 1 and 2. Twelve patients were treated with a median of 2 cycles of Dolastatin-10, and no patient experienced an objective response. The only grade >2 toxicities were grade 3 neutropenia uncomplicated by infection, occurring in 4 patients following the first treatment cycle. The total systemic clearance and volume of distribution at steady-state were 2.61 ± 1.9 L/h/m2 and 28.4 ± 13 L/m2, respectively. Due to prolonged terminal elimination, Dolastatin-10 plasma concentrations of greater than 1 nM were sustained for 24 h in all patients studied. Dolastatin-10 is unlikely to have substantial activity in the treatment of melanoma.

Original languageEnglish (US)
Pages (from-to)335-340
Number of pages6
JournalInvestigational New Drugs
Volume19
Issue number4
DOIs
StatePublished - 2001

Fingerprint

dolastatin 10
Melanoma
Neoplasms
Mollusca
Neutropenia
Microtubules

Keywords

  • Dolastatin-10
  • Metastatic melanoma
  • Pharmokinetics

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

Dolastatin-10 in metastatic melanoma : A phase II and pharmokinetic trial of the California Cancer Consortium. / Margolin, Kim; Longmate, Jeffrey; Synold, Timothy W.; Gandara, David R; Weber, Jeffrey; Gonzalez, Rene; Johansen, Mary J.; Newman, Robert; Baratta, Tracey; Doroshow, James H.

In: Investigational New Drugs, Vol. 19, No. 4, 2001, p. 335-340.

Research output: Contribution to journalArticle

Margolin, K, Longmate, J, Synold, TW, Gandara, DR, Weber, J, Gonzalez, R, Johansen, MJ, Newman, R, Baratta, T & Doroshow, JH 2001, 'Dolastatin-10 in metastatic melanoma: A phase II and pharmokinetic trial of the California Cancer Consortium', Investigational New Drugs, vol. 19, no. 4, pp. 335-340. https://doi.org/10.1023/A:1010626230081
Margolin, Kim ; Longmate, Jeffrey ; Synold, Timothy W. ; Gandara, David R ; Weber, Jeffrey ; Gonzalez, Rene ; Johansen, Mary J. ; Newman, Robert ; Baratta, Tracey ; Doroshow, James H. / Dolastatin-10 in metastatic melanoma : A phase II and pharmokinetic trial of the California Cancer Consortium. In: Investigational New Drugs. 2001 ; Vol. 19, No. 4. pp. 335-340.
@article{f237564c1bb0466cb0bbe91be74f45f8,
title = "Dolastatin-10 in metastatic melanoma: A phase II and pharmokinetic trial of the California Cancer Consortium",
abstract = "Dolastatin-10 is a novel pentapeptide agent originally isolated from the marine mollusk Dolabella auricularia with a mechanism of antitumor activity that involves the inhibition of microtubule assembly. We performed a Phase II trial of Dolastatin-10, 400 μg/m2, in patients with advanced melanoma who had received no prior chemotherapy. Dolastatin-10 pharmokinetics were evaluated in a subset of patients following courses 1 and 2. Twelve patients were treated with a median of 2 cycles of Dolastatin-10, and no patient experienced an objective response. The only grade >2 toxicities were grade 3 neutropenia uncomplicated by infection, occurring in 4 patients following the first treatment cycle. The total systemic clearance and volume of distribution at steady-state were 2.61 ± 1.9 L/h/m2 and 28.4 ± 13 L/m2, respectively. Due to prolonged terminal elimination, Dolastatin-10 plasma concentrations of greater than 1 nM were sustained for 24 h in all patients studied. Dolastatin-10 is unlikely to have substantial activity in the treatment of melanoma.",
keywords = "Dolastatin-10, Metastatic melanoma, Pharmokinetics",
author = "Kim Margolin and Jeffrey Longmate and Synold, {Timothy W.} and Gandara, {David R} and Jeffrey Weber and Rene Gonzalez and Johansen, {Mary J.} and Robert Newman and Tracey Baratta and Doroshow, {James H.}",
year = "2001",
doi = "10.1023/A:1010626230081",
language = "English (US)",
volume = "19",
pages = "335--340",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "4",

}

TY - JOUR

T1 - Dolastatin-10 in metastatic melanoma

T2 - A phase II and pharmokinetic trial of the California Cancer Consortium

AU - Margolin, Kim

AU - Longmate, Jeffrey

AU - Synold, Timothy W.

AU - Gandara, David R

AU - Weber, Jeffrey

AU - Gonzalez, Rene

AU - Johansen, Mary J.

AU - Newman, Robert

AU - Baratta, Tracey

AU - Doroshow, James H.

PY - 2001

Y1 - 2001

N2 - Dolastatin-10 is a novel pentapeptide agent originally isolated from the marine mollusk Dolabella auricularia with a mechanism of antitumor activity that involves the inhibition of microtubule assembly. We performed a Phase II trial of Dolastatin-10, 400 μg/m2, in patients with advanced melanoma who had received no prior chemotherapy. Dolastatin-10 pharmokinetics were evaluated in a subset of patients following courses 1 and 2. Twelve patients were treated with a median of 2 cycles of Dolastatin-10, and no patient experienced an objective response. The only grade >2 toxicities were grade 3 neutropenia uncomplicated by infection, occurring in 4 patients following the first treatment cycle. The total systemic clearance and volume of distribution at steady-state were 2.61 ± 1.9 L/h/m2 and 28.4 ± 13 L/m2, respectively. Due to prolonged terminal elimination, Dolastatin-10 plasma concentrations of greater than 1 nM were sustained for 24 h in all patients studied. Dolastatin-10 is unlikely to have substantial activity in the treatment of melanoma.

AB - Dolastatin-10 is a novel pentapeptide agent originally isolated from the marine mollusk Dolabella auricularia with a mechanism of antitumor activity that involves the inhibition of microtubule assembly. We performed a Phase II trial of Dolastatin-10, 400 μg/m2, in patients with advanced melanoma who had received no prior chemotherapy. Dolastatin-10 pharmokinetics were evaluated in a subset of patients following courses 1 and 2. Twelve patients were treated with a median of 2 cycles of Dolastatin-10, and no patient experienced an objective response. The only grade >2 toxicities were grade 3 neutropenia uncomplicated by infection, occurring in 4 patients following the first treatment cycle. The total systemic clearance and volume of distribution at steady-state were 2.61 ± 1.9 L/h/m2 and 28.4 ± 13 L/m2, respectively. Due to prolonged terminal elimination, Dolastatin-10 plasma concentrations of greater than 1 nM were sustained for 24 h in all patients studied. Dolastatin-10 is unlikely to have substantial activity in the treatment of melanoma.

KW - Dolastatin-10

KW - Metastatic melanoma

KW - Pharmokinetics

UR - http://www.scopus.com/inward/record.url?scp=0034851434&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034851434&partnerID=8YFLogxK

U2 - 10.1023/A:1010626230081

DO - 10.1023/A:1010626230081

M3 - Article

VL - 19

SP - 335

EP - 340

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 4

ER -